More than 25 years of genetic studies of clozapine-induced agranulocytosis

  title={More than 25 years of genetic studies of clozapine-induced agranulocytosis},
  author={Sera A. J. With and S.L. Pulit and Wouter G. Staal and Ren{\'e} S. Kahn and R. A. Ophoff},
  journal={The Pharmacogenomics Journal},
Clozapine is one of the most effective atypical antipsychotic drugs prescribed to patients with treatment-resistant schizophrenia. Approximately 1% of patients experience potential life-threatening adverse effects in the form of agranulocytosis, greatly hindering its applicability in clinical practice. The etiology of clozapine-induced agranulocytosis (CIA) remains unclear, but is thought to be a heritable trait. We reviewed the genetic studies of CIA published thus far. One recurrent finding… 

Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective

An overview of the current understanding of the genetics of clozapine-associated agranulocytosis and neutropenia is provided and recent findings relating to the Duffy-null genotype and its association with benign neutropania in individuals with African ancestry are described.

Genetic associations with clozapine-induced myocarditis in patients with schizophrenia

Novel candidate genetic associations with clozapine-induced myocarditis are reported, which may have potential clinical utility, but larger cohorts are required for replication.

Severe clozapine-induced agranulocytosis: successful treatment with G-CSF and rechallenge of clozapine plus D2 potentiation therapy (amisulpride).

During 5 years of follow-up of a cohort of 271 patients treated with clozapine in Spain, the incidence of benign leukopenia was only 1.3% and no cases of agranulocytosis were described.

Genetic risk of clozapine-induced leukopenia and neutropenia: a genome-wide association study

A genome-wide association study in a Chinese population provides novel and valuable understanding of the genetic and immune causes of CIL and CIN, which is useful for improving clinical management of clozapine related treatment for schizophrenia.

Safety of a Clozapine Trial Following Quetiapine-Induced Leukopenia: A Case Report.

The safety of clozapine in a patient who has previously experienced leukopenia and neutropenia with quetiapine requires further investigation and increased attention should be paid to such cases.

New findings in pharmacogenetics of schizophrenia

The findings to date are promising and provide a better understanding of the development of side effects and response to antipsychotics, however, more comprehensive investigations in large, well characterized samples will bring us closer to clinically actionable findings.

Late-Onset Clozapine-Induced Agranulocytosis in a Young Woman with Paranoid Schizophrenia

A case which has developed agranulocytosis in the later stages of clozapine treatment is discussed, which is considered to be the better promising drug in the treatment of paranoid schizophrenia with minimal side effects.

Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring

Clozapine-induced agranulocytosis/granulocytopenia (CIAG) is an uncommon condition, but potentially fatal in consequences, and the current theory suggests reactive oxygen species – nitrenium ion as the most important factor of CIAG.


More research is needed on the matter in the interest of a better quality of life for treatment resistant schizophrenia patients, as evidence suggest rechallenging after clozapine-induced neutropenia.

Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

The aim of this paper is to briefly summarize and provide an update on major clozapine adverse effects, especially focusing on those that are severe and potentially life threatening, even if most of the latter are relatively uncommon.



Establishing the characteristics of an effective pharmacogenetic test for clozapine induced agranulocytosis

A pharmacogenetic test is clinically useful if it identifies a group of patients for whom the agranulocytosis risk is low enough to alleviate monitoring requirements and is essential for clinical utility, in particular in combination with a small high risk group.

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.

Relation of the Allelic Variants of Multidrug Resistance Gene to Agranulocytosis Associated With Clozapine

Patients with CAA had shorter duration of clozapine use but did not show any significant difference in other clinical, sociodemographic characteristics and in genotypic or allelic distributions of ABCB1 variants and haplotypes compared with control patients.

Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles

Two loci in the major histocompatibility complex are independently associated with clozapine-induced agranulocytosis/granulocytopenia (CIAG), and these associations dovetail with the roles of these genes in immunogenetic phenotypes and adverse drug responses for other medications, and provide insight into the pathophysiology of CIAG.

Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6.

Lack of evidence of an association of CA and genetically variable activity of these specific drug metabolizing enzyme systems of clozapine is suggested; however, this may be due to statistical reasons only.

Drug-Induced Agranulocytosis: Impact of Different Fcγ Receptor Polymorphisms?

Fcγ receptors may not serve as a genetic marker to identify patients at risk for this life-threatening side effect of clozapine-induced agranulocytosis, and no further associations are found that underline an effect of polymorphisms in FcγRIIa, F cγRIIIa, and Fc�RIIIb genes.

Exome sequence analysis of Finnish patients with clozapine-induced agranulocytosis

The association of CNR1 variants with psychotomimetic effects induced by cannabis at first use could accurately reflect the genetic risk of psychosis when exposed to cannabis, by avoiding the confounding factors of preexisting psychosis or the association of these genetic variants to psychosis or addiction.

Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens

Human leukocyte antigen genotyping and haplotype analyses in patients suffering from CA and patients treated with clozapine without developing CA obtained significant association results with CA, but only HLA associations with CA are identified as clinically relevant.

Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups.

The results show a strong association of some genetic variants of the TNF loci with susceptibility to CA in two different ethnic groups suggesting involvement of TNF and/or associated gene(s) products in the pathogenesis of this hematologic-drug adverse reaction.